BACKGROUND: Reduced intensity conditioning regimens permit the delivery of a potentially curative graft-versus-leukemia effect in older patients with acute myeloid leukemia. Although T-cell depletion is increasingly used to reduce the risk of graft-versus-host disease its impact on the graft-versus-leukemia effect and long-term outcome post-transplant is unknown. DESIGN AND METHODS: We have characterized pre- and post-transplant factors determining overall survival in 168 patients with acute myeloid leukemia transplanted using an alemtuzumab based reduced intensity conditioning regimen with a median duration of follow-up of 37 months. RESULTS: The 3-year overall survival for patients transplanted in CR1 or CR2/CR3 was 50% (95% CI, 38% to 62%) and 44% (95% CI, 31% to 56%), respectively compared to 15% (95% CI, 2% to 36%) for patients with relapsed/refractory disease. Multivariate analysis demonstrated that both survival and disease relapse were influenced by status at transplant (P=0.008) and presentation cytogenetics (P=0.01). Increased exposure to cyclosporine A (CsA) in the first 21 days post-transplant was associated with an increased relapse risk (P<0.0001) and decreased overall survival (P<0.0001). CONCLUSIONS: Disease stage, presentation karyotype and post-transplant CsA exposure are important predictors of outcome in patients undergoing a T-cell depleted reduced intensity conditioning allograft for acute myeloid leukemia. These data confirm the presence of a potent graft-versus-leukemia effect after a T-cell depleted reduced intensity conditioning allograft in acute myeloid leukemia and identify CsA exposure as a manipulable determinant of outcome in this setting.
BACKGROUND: Reduced intensity conditioning regimens permit the delivery of a potentially curative graft-versus-leukemia effect in older patients with acute myeloid leukemia. Although T-cell depletion is increasingly used to reduce the risk of graft-versus-host disease its impact on the graft-versus-leukemia effect and long-term outcome post-transplant is unknown. DESIGN AND METHODS: We have characterized pre- and post-transplant factors determining overall survival in 168 patients with acute myeloid leukemia transplanted using an alemtuzumab based reduced intensity conditioning regimen with a median duration of follow-up of 37 months. RESULTS: The 3-year overall survival for patients transplanted in CR1 or CR2/CR3 was 50% (95% CI, 38% to 62%) and 44% (95% CI, 31% to 56%), respectively compared to 15% (95% CI, 2% to 36%) for patients with relapsed/refractory disease. Multivariate analysis demonstrated that both survival and disease relapse were influenced by status at transplant (P=0.008) and presentation cytogenetics (P=0.01). Increased exposure to cyclosporine A (CsA) in the first 21 days post-transplant was associated with an increased relapse risk (P<0.0001) and decreased overall survival (P<0.0001). CONCLUSIONS: Disease stage, presentation karyotype and post-transplant CsA exposure are important predictors of outcome in patients undergoing a T-cell depleted reduced intensity conditioning allograft for acute myeloid leukemia. These data confirm the presence of a potent graft-versus-leukemia effect after a T-cell depleted reduced intensity conditioning allograft in acute myeloid leukemia and identify CsA exposure as a manipulable determinant of outcome in this setting.
Authors: A Bacigalupo; V Vitale; R Corvò; S Barra; T Lamparelli; F Gualandi; N Mordini; G Berisso; S Bregante; A M Raiola; M T Van Lint; F Frassoni Journal: Br J Haematol Date: 2000-01 Impact factor: 6.998
Authors: Ronjon Chakraverty; Karl Peggs; Rajesh Chopra; Donald W Milligan; Panagiotis D Kottaridis; Stephanie Verfuerth; Johanne Geary; Dharsha Thuraisundaram; Kate Branson; Suparno Chakrabarti; Premini Mahendra; Charles Craddock; Anne Parker; Ann Hunter; Geoff Hale; Herman Waldmann; Catherine D Williams; Kwee Yong; David C Linch; Anthony H Goldstone; Stephen Mackinnon Journal: Blood Date: 2002-02-01 Impact factor: 22.113
Authors: P A McSweeney; D Niederwieser; J A Shizuru; B M Sandmaier; A J Molina; D G Maloney; T R Chauncey; T A Gooley; U Hegenbart; R A Nash; J Radich; J L Wagner; S Minor; F R Appelbaum; W I Bensinger; E Bryant; M E Flowers; G E Georges; F C Grumet; H P Kiem; B Torok-Storb; C Yu; K G Blume; R F Storb Journal: Blood Date: 2001-06-01 Impact factor: 22.113
Authors: S Slavin; A Nagler; E Naparstek; Y Kapelushnik; M Aker; G Cividalli; G Varadi; M Kirschbaum; A Ackerstein; S Samuel; A Amar; C Brautbar; O Ben-Tal; A Eldor; R Or Journal: Blood Date: 1998-02-01 Impact factor: 22.113
Authors: P D Kottaridis; D W Milligan; R Chopra; R K Chakraverty; S Chakrabarti; S Robinson; K Peggs; S Verfuerth; R Pettengell; J C Marsh; S Schey; P Mahendra; G J Morgan; G Hale; H Waldmann; M C Ruiz de Elvira; C D Williams; S Devereux; D C Linch; A H Goldstone; S MacKinnon Journal: Cytotherapy Date: 2001 Impact factor: 5.414
Authors: Karl S Peggs; Kirsty Thomson; Daniel P Hart; Johanne Geary; Emma C Morris; Kwee Yong; Anthony H Goldstone; David C Linch; Stephen Mackinnon Journal: Blood Date: 2003-10-23 Impact factor: 22.113
Authors: John Koreth; Richard Schlenk; Kenneth J Kopecky; Sumihisa Honda; Jorge Sierra; Benjamin J Djulbegovic; Martha Wadleigh; Daniel J DeAngelo; Richard M Stone; Hisashi Sakamaki; Frederick R Appelbaum; Hartmut Döhner; Joseph H Antin; Robert J Soiffer; Corey Cutler Journal: JAMA Date: 2009-06-10 Impact factor: 56.272
Authors: H G Sayer; M Kröger; J Beyer; M Kiehl; S A Klein; K Schaefer-Eckart; R Schwerdtfeger; W Siegert; V Runde; C Theuser; H Martin; J Schetelig; D W Beelen; A Fauser; J Kienast; K Höffken; G Ehninger; M Bornhäuser Journal: Bone Marrow Transplant Date: 2003-06 Impact factor: 5.483
Authors: Amir A Toor; Roy T Sabo; Harold M Chung; Catherine Roberts; Rose H Manjili; Shiyu Song; David C Williams; Wendy Edmiston; Mandy L Gatesman; Richard W Edwards; Andrea Ferreira-Gonzalez; William B Clark; Michael C Neale; John M McCarty; Masoud H Manjili Journal: Biol Blood Marrow Transplant Date: 2011-10-17 Impact factor: 5.742
Authors: Michel Duval; John P Klein; Wensheng He; Jean-Yves Cahn; Mitchell Cairo; Bruce M Camitta; Rammurti Kamble; Edward Copelan; Marcos de Lima; Vikas Gupta; Armand Keating; Hillard M Lazarus; Mark R Litzow; David I Marks; Richard T Maziarz; David A Rizzieri; Gary Schiller; Kirk R Schultz; Martin S Tallman; Daniel Weisdorf Journal: J Clin Oncol Date: 2010-07-12 Impact factor: 44.544
Authors: A Bryant; I Nivison-Smith; E S Pillai; G Kennedy; A Kalff; D Ritchie; B George; M Hertzberg; S Patil; A Spencer; K Fay; P Cannell; L Berkahn; R Doocey; R Spearing; J Moore Journal: Bone Marrow Transplant Date: 2013-09-23 Impact factor: 5.483